Russian Vaccine POLYMILEX Wide Prospects
Manufacture of innovative vaccines and biotechnological products has been launched in Russia. The manufacture, meeting global quality standards and based on modern technologies, partially marketed in Russia, was initiated at Biomedical complex Nanolek in the Kirov Region.
POLYMILEXÒ, inactivated polio vaccine (marketing authorization is pending) will be manufactured at that site. Transfer of technology to the BMK site in partnership with Bilthoven Biologicals (Netherlands) started in 2012 and is close to completion. POLYMILEXÒ will be the first inactivated polio vaccine to be manufactured in Russia. It will be supplied for the needs of Russian Healthcare starting with 2017.
Taking into account the deficiency of inactivated polio vaccine globally, it is expected that it will enter international markets, including UNICEF.
Vladimir Khristenko, President of NANOLEK at the gala opening shared the ambition of NANOLEK to become one of the leading vaccine manufacturers in Russia, integrating investments and global experience, as well as experience of international partners.
Investment period of company development is completed. Implementation of projects for manufacture of partner products is starting. A lot has been done, but more will be done, considering manufacturing capacities of NANOLEK complex, the ability to extend capacities and broad prospects in the field of development of innovative drugs.